



AURIGENE

PHARMACEUTICAL SERVICES

You Voted

Here's What We See in Real Peptide Programs

Poll Results

Aggregation & Stability Issues

45%

Impurity Control at Scale

35%

Purification Complexity

13%

Sourcing Unnatural Amino Acids

7%

And in one bicyclic peptide program, we encountered all four.





AURIGENE

PHARMACEUTICAL SERVICES


The Challenge

Multiple unnatural amino acids
not readily available in the
market

Dimeric impurities from
free indole side chains

Aggregation and stability issues
during linear peptide isolation

Complex synthesis requiring
multiple RP-HPLC purifications
and lyophilization steps





AURIGENE

PHARMACEUTICAL SERVICES

Our Approach

We rebuilt the synthesis end-to-end:

Telescoped the linear peptide
directly into oxidative bridging
aggregation avoided



Refined coupling strategy for
free indole amino acids to
minimize dimers



Reduced purification and
lyophilization steps for simpler
manufacturing



Conducted process optimization
across every stage



Designed and developed in-house
unnatural amino acids






AURIGENE

PHARMACEUTICAL SERVICES

The Impact





AURIGENE

PHARMACEUTICAL SERVICES

Scale-Up Success

Delivered 3 kg
non-GMP
supplies

9 kg cGMP
manufacturing
in progress

2nd-generation
process under
development
for further
optimization





AURIGENE

PHARMACEUTICAL SERVICES

Unlock complex peptide challenges with confidence

Whether it's unnatural amino acids, bicyclic structures, or scale-up - we partner from discovery to cGMP.

